XML 48 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Compensation (Tables)
3 Months Ended
Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the three months ended September 30, 2018 is as follows:

 

 

 

Number

of

shares

 

 

Weighted

average

exercise

price

 

Options outstanding at June 30, 2018

 

 

6.3

 

 

$

24.50

 

Options granted

 

 

 

 

$

 

Less:

 

 

 

 

 

 

 

 

Options exercised

 

 

(0.6

)

 

$

23.84

 

Options canceled or expired

 

 

 

 

$

 

Options outstanding at September 30, 2018

 

 

5.7

 

 

$

24.57

 

Options exercisable at September 30, 2018

 

 

5.7

 

 

$

24.57

 

 

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of the RSU activity under the Company’s plans for the three months ended September 30, 2018 is as follows:

 

 

 

Number

of

shares

 

 

Weighted

average

grant date

fair value

 

RSUs outstanding at June 30, 2018

 

 

2.2

 

 

$

31.12

 

RSUs granted

 

 

1.1

 

 

$

47.81

 

Less:

 

 

 

 

 

 

 

 

RSUs vested

 

 

(0.8

)

 

$

32.39

 

RSUs canceled

 

 

 

 

$

 

RSUs outstanding at September 30, 2018

 

 

2.5

 

 

$

38.06

 

 

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:

 

 

 

Three months ended

 

 

 

September 30,

 

 

 

2018

 

 

2017

 

Cost of molecular diagnostic testing

 

$

0.2

 

 

$

0.2

 

Cost of pharmaceutical and clinical services

 

 

0.1

 

 

 

0.1

 

Research and development expense

 

 

1.2

 

 

 

0.8

 

Selling, general, and administrative expense

 

 

6.2

 

 

 

5.3

 

Total share-based compensation expense

 

$

7.7

 

 

$

6.4